# IV NAD Therapy in the Research Literature — NAD+ Evidence, Pharmacokinetics, and Risks > IV NAD therapy summarized from the research: an unapproved compounded route with weak controlled evidence, rapid plasma clearance, and a documented Class I endotoxin recall. NAD+ research framing only. The injectable route is the most aggressively marketed and the least supported by controlled human evidence. Here is what the published research — and the safety record — actually shows. ## In plain English **IV NAD therapy** means dripping NAD+ (the cell's energy-handling coenzyme) straight into a vein instead of swallowing a precursor pill. It is offered at wellness clinics, but it is not FDA-approved, the preparations are compounded (mixed to order rather than manufactured as an approved drug), and the controlled human evidence behind it is thin. Two facts dominate this page: infused NAD+ leaves the bloodstream within about two hours, and a compounded NAD+ injection has been recalled for contamination. This is a summary of the research, not a recommendation to seek out any infusion. ## What an IV NAD+ infusion is — and is not IV NAD+ delivers the finished coenzyme directly into the circulation, bypassing the absorption problem that makes oral NAD+ inefficient. It is used in wellness and some clinical settings, but its regulatory standing is specific and worth stating plainly: it is an unapproved, compounded preparation, not an FDA-approved treatment for any condition. "Compounded" means each batch is prepared by a pharmacy rather than manufactured and tested as an approved drug, which is exactly where the quality-control risk enters. The published evidence base for IV NAD+ is dominated by pilot studies, retrospective reports, and animal work rather than randomized controlled trials. That is the defining feature of this route: it is delivered confidently in the marketplace and supported thinly in the literature. ## The pharmacokinetics: rapid plasma clearance The central pharmacological fact about IV NAD+ is how quickly it disappears. A pilot pharmacokinetic study found that infused NAD+ was near-completely removed from plasma within the first roughly two hours of infusion. NAD+ is not freely taken up intact by most cells, so a large intravenous dose does not behave like a sustained reservoir — it is cleared, metabolized, and gone within hours. The contrast with oral precursors is sharp. NR and NMN, taken by mouth, raise whole-blood NAD+ over days and hold that elevation through weeks of dosing [3][4]. An IV bolus produces a transient plasma spike that the body clears quickly. Any claim that an infusion "restores" NAD+ durably has to be read against that clearance curve. ## Animal data are strong; controlled human data are not The animal evidence for intravenous NAD+ is genuinely striking. In a rat model of myocardial ischemia-reperfusion, IV NAD+ at 10-20 mg/kg dose-dependently reduced infarct size — about an 85% reduction at 20 mg/kg — alongside reduced apoptotic markers and enhanced superoxide dismutase antioxidant capacity [9]. Related preclinical work shows NMN protecting the mouse heart from ischemia-reperfusion via NAD+ salvage and SIRT1 [7], and NAD+ precursors preventing kidney injury in mouse models [6]. But these are rodent results, and the route, dose, and timing do not translate into a human protocol. The strongest IV findings live almost entirely in animals; the human side of IV NAD+ remains pilot-grade. A 2025 review of NAD+ supplementation in human ageing concluded that efficacy for hard endpoints remains preliminary [15] — and IV NAD+ has the weakest controlled human evidence of any route. ## The documented safety hazard IV NAD+ is where the safety record turns concrete. Infusion-related effects — flushing, nausea, and chest or abdominal discomfort — are common when an infusion is run too fast, and are typically transient and rate-dependent. The more serious, documented hazard is contamination. The FDA has issued a Class I recall — its most serious recall category — of a compounded NAD+ injection over elevated bacterial endotoxin. A Class I designation means a reasonable probability of serious harm or death. Reconstituted injectable NAD+ is also hygroscopic and should be kept cold and protected from light. Compounded sterile injectables that fail quality control are a known patient-safety problem, and the NAD+ recall is a specific instance of it. This site documents that record; it does not direct anyone toward an infusion. ## What is an NAD injection? An NAD injection delivers NAD+ itself — not an oral precursor — by the intravenous, subcutaneous, or intramuscular route, using a compounded preparation that is not FDA-approved. Infused NAD+ is rapidly cleared from plasma, and controlled human evidence for injectable routes is limited compared with the oral-precursor trials [3][4]. It is the route with the most marketing and the least controlled data. ## When is injectable NAD+ given in studies? Published injectable and IV protocols describe infusions of roughly 250-1000 mg per session over several hours, and one pharmacokinetic study used a 3 µmol/min continuous infusion over six hours. These are study and clinic descriptions reported for context, not dosing or timing instructions — no human protocol is recommended here. ## Is an NAD+ shot worth it? The published evidence for injectable or IV NAD+ is mostly preclinical or pilot-grade. A 2025 review concluded that human efficacy for hard endpoints remains preliminary [15], and IV NAD+ specifically has the weakest controlled human evidence of any route. This site summarizes that research rather than recommending or discouraging any product. ## Does NAD IV actually work? By controlled-evidence standards, IV NAD+ is the least-supported route. Infused NAD+ is cleared from plasma within about two hours, and most human claims rest on pilot or retrospective reports rather than randomized trials. The animal IV cardiac result is dramatic — roughly 85% infarct-size reduction at 20 mg/kg in rats [9] — but it has not been shown to translate into proven human outcomes. ## Is NAD safe? For oral precursors, trials over 8-12 weeks reported general tolerability and no significant adverse-event difference from placebo [4]. For the injectable route, the central documented concern is a compounded NAD+ injection that drew an FDA Class I recall for endotoxin contamination. Infusion-rate-related flushing and nausea are also reported. Safety differs sharply by route. --- A nocturnal traverse of the NAD+ literature — the heart, kidney, and muscle studies cited to source, the precursor-not-NAD+ distinction kept exact, and the trail marked where the human evidence thins; no clinic at the trailhead and nothing here dispensed, prescribed, or sold.